Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Pharmaceuticals has introduced a generic version of Exelon (rivastigmine tartrate) capsules of strengths 1.5mg, 3mg, 4.5mg and 6mg.
Subscribe to our email newsletter
Watson Pharmaceuticals said that the launch was a part of a settlement agreement with Novartis Pharmaceuticals, Novartis Pharma, Novartis AG, Novartis International, and Proterra (collectively Novartis).
Exelon is used to treat dementia in people suffering with Alzheimer’s disease. Exelon is known to improve the function of nerve cells in the brain. It works by preventing the breakdown of a chemical called acetylcholine.
As per the terms of the agreement between Watson and Novartis in December 6, 2007, Watson has received license to Novartis’ US patents covering Exelon for a generic version of Exelon.
Watson received approval from FDA on January 8, 2008, for its abbreviated new drug application of generic version of Exelon.